Black Cohosh
8 benefits mapped to clinical evidence across supplements.
Dose per serving from products
465 products in our catalogue print how much Black Cohosh a serving holds.
Most common: 25 mg to 50 mg, 31% of 465 products.
| Dose per serving | Products |
|---|---|
| 10 mg or less | 8 |
| 10 mg to 25 mg | 25 |
| 25 mg to 50 mg | 142 |
| 50 mg to 100 mg | 82 |
| 100 mg to 250 mg | 99 |
| 250 mg to 500 mg | 26 |
| 500 mg to 1 g | 80 |
| over 1 g | 3 |
Dose per serving from research
20 study groups in 18 studies say how much Black Cohosh participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 55% of 20 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg or less | 1 |
| 25 mg to 50 mg | 11 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 3 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 1 |
| over 1 g | 1 |
Benefit Evidence
Symptom relief; hormones unchanged
Hot flashes −85%
Endometrium: no estrogenic change
Symptom relief; hormones unchanged
Hot flashes −85%
Endometrium: no estrogenic change
Research sources
Hormone balance (18)
- Adding the phytoestrogen Cimicifugae Racemosae to clomiphene induction cycles with timed intercourse in polycystic ovary syndrome improves cycle outcomes and pregnancy rates - a randomized trial
PubMed ID: 24592984
Adding Cimicifuga to clomiphene cycles significantly increased midcycle/midluteal estradiol and endometrial thickness and nearly doubled pregnancy rates.
- Black cohosh improves objective sleep in postmenopausal women with sleep disturbance
PubMed ID: 26000551
Objective sleep study showed improved sleep efficiency and reduced WASO in early postmenopausal women on black cohosh, implying fewer/night sweat‑related awakenings.
- Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women
PubMed ID: 29198157
C. foetida reduced menopausal symptom scores without adverse effects on liver/kidney/endometrium over follow‑up.
- Effect of cimicifuga racemosa on menopausal syndrome caused by LHRH-a in breast cancer
PubMed ID: 30935866
Remifemin reduced menopausal symptoms in breast cancer patients receiving LHRH‑a without major hormonal changes.
- Comparison Of Cimicifuga foetida extract and different hormone therapies regarding in causing breast pain in early postmenopausal women
PubMed ID: 30324837
C. foetida reduced breast pain and associated symptoms vs hormone therapies which can contribute to menopausal symptom burden.
- Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer
PubMed ID: 12609560
Open-label RCT adjunct to tamoxifen reported substantial reductions in number and severity of hot flashes (clinically large effect).
- The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers
PubMed ID: 12609561
Double-blind RCT showing CR extract relieved menopausal symptoms similarly to low-dose estrogen—solid evidence.
- Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms
PubMed ID: 15863547
Large RCT showed significant improvement in the hot-flush subscore vs placebo—strong direct evidence.
- Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol
PubMed ID: 15969244
3-month RCT found CR reduced hot flashes comparably to low-dose estradiol—supports hot-flush benefit.
- First-time proof of endometrial safety of the special black cohosh extract (Actaea or Cimicifuga racemosa extract) CR BNO 1055
PubMed ID: 16837890
1-year prospective study reported marked reduction in hot flushes though open-label and uncontrolled.
- Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial
PubMed ID: 17565936
RCT vs fluoxetine reported larger hot-flush reductions with black cohosh (-85% vs -62%) but lacked placebo—supportive albeit limited by design.
- Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone
PubMed ID: 17587516
High-quality double-blind non-inferiority trial vs active hormonal therapy showing large KMI reductions (~-69%)—strong support.
- Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study
PubMed ID: 17454163
Small randomized pilot with a multi-herb complex including black cohosh reported large night-sweat reductions (-69%) and sleep improvement; attribution uncertain.
- [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms]
PubMed ID: 20003788
Remifemin produced large reductions in KMI similar to tibolone but with fewer hormone‑related adverse events.
- Supplementation of clomiphene citrate cycles with Cimicifuga racemosa or ethinyl oestradiol--a randomized trial
PubMed ID: 19909590
Cimicifuga/phytoestrogen supplement improved endometrial thickness and estradiol in clomiphene cycles though pregnancy rate not significantly higher.
- Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms
PubMed ID: 22157510
Large multicenter RCT: standardized Remifemin significantly reduced menopausal symptoms vs placebo.
- Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women
PubMed ID: 23769553
Cimicifuga foetida reduced KMI and MENQOL scores vs comparators (though somewhat less than HRT).
- Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome
PubMed ID: 23347605
In PCOS patients, Cimicifuga extract improved ovulation markers and endometrial thickness versus clomiphene.
Wellbeing (8)
- Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms
PubMed ID: 22157510
Large multicenter RCT: standardized Remifemin significantly reduced menopausal symptom severity and was well tolerated.
- Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women
PubMed ID: 23769553
C. foetida reduced KMI and improved MENQOL domains vs HRT with lower bleeding — supports QOL benefit.
- Efficacy and safety evaluation of Cimicifuga foetida extract in menopausal women
PubMed ID: 29198157
C. foetida reduced menopausal symptom scores over follow‑up with no safety signals; supports sustained symptom/QOL improvement.
- Assessing the combined effects of Black Cohosh, Soy Isoflavones, and SDG Lignans on menopausal symptoms: a randomized, double-blind, placebo-controlled clinical trial
PubMed ID: 40131516
Multi‑ingredient trial including black cohosh produced large, significant reductions in Menopause Rating Scale total and domains — overall QOL improved though attribution uncertain.
- The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers
PubMed ID: 12609561
Double-blind RCT showed Cimicifuga comparable to low-dose estrogen for menopausal symptom relief—supports overall well-being benefit.
- Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms
PubMed ID: 15863547
Large double-blind RCT showed significant improvement in Menopause Rating Scale and climacteric symptoms vs placebo—supports general well-being improvement.
- Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone
PubMed ID: 17587516
Non-inferiority RCT vs tibolone showed large KMI reductions (~68.8%) and good tolerability—supports clinically meaningful overall symptom improvement.
- [Efficacy and safety of remifemin compared to tibolone for controlling of perimenopausal symptoms]
PubMed ID: 20003788
Remifemin reduced Kupperman scores comparably to tibolone with fewer side effects (meaningful symptom/QOL benefit).
Sexual wellness (4)
- Adding phytoestrogens to clomiphene induction in unexplained infertility patients--a randomized trial
PubMed ID: 18413068
Randomized trial adding Cimicifuga to clomiphene cycles showed substantially higher pregnancy rates and improved endometrial thickness/progesterone—meaningful reproductive/sexual wellness outcome.
- Role of phyto-oestrogens in ovulation induction in women with polycystic ovarian syndrome
PubMed ID: 23347605
Cimicifuga extract improved ovulatory markers and endometrial thickness in PCOS patients — supportive of reproductive/sexual function.
- Supplementation of clomiphene citrate cycles with Cimicifuga racemosa or ethinyl oestradiol--a randomized trial
PubMed ID: 19909590
Improved endometrial thickness and estradiol in clomiphene cycles, though pregnancy rates were not significantly higher in that trial.
- Adding the phytoestrogen Cimicifugae Racemosae to clomiphene induction cycles with timed intercourse in polycystic ovary syndrome improves cycle outcomes and pregnancy rates - a randomized trial
PubMed ID: 24592984
In infertile/PCOS contexts, adding Cimicifuga to clomiphene improved endometrial thickness, estradiol, and substantially increased clinical pregnancy rates — relevant to sexual/reproductive wellness.
Mood balance (3)
- Menopause: a standardized isopropanolic black cohosh extract (remifemin) is found to be safe and effective for menopausal symptoms
PubMed ID: 22157510
Large RCT of Remifemin reported overall menopausal symptom reduction including psychological domains (supports mood/QOL benefit).
- Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women
PubMed ID: 23769553
Cimicifuga foetida reduced menopausal symptom scores and produced modest anxiety/mood improvements vs HRT comparators.
- [Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression]
PubMed ID: 23663341
Adding remifemin to paroxetine modestly improved depression outcomes vs paroxetine alone (randomized trial).
Bone health (2)
- The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers
PubMed ID: 12609561
Randomized double-blind RCT showed beneficial changes in bone markers with Cimicifuga versus estrogen/placebo—supports bone marker effects.
- Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: a double-blind, placebo-controlled, and conjugated estrogens-controlled study
PubMed ID: 16645532
Double-blind study demonstrated modest stimulation of osteoblast marker (bone-specific alkaline phosphatase) vs placebo; short duration and surrogate markers only.
Sleep quality (2)
- Phyto-Female Complex for the relief of hot flushes, night sweats and quality of sleep: randomized, controlled, double-blind pilot study
PubMed ID: 17454163
Small RCT of a multi-herb formula (including black cohosh) reported improved sleep over 3 months—direct positive finding but multi-ingredient.
- Black cohosh improves objective sleep in postmenopausal women with sleep disturbance
PubMed ID: 26000551
Polysomnography RCT showed significant objective improvements in sleep efficiency and reduced WASO with black cohosh.
Stress & Anxiety (1)
- Efficacy and safety of Cimicifuga foetida extract on menopausal syndrome in Chinese women
PubMed ID: 23769553
Reported modest reductions in anxiety scores with Cimicifuga foetida in early menopausal women.
Blood circulation (1)
- Effectiveness of the short-term use of Cimicifuga racemosa in the endothelial function of postmenopausal women: a double-blind, randomized, controlled trial
PubMed ID: 31691621
Short‑term randomized trial showed significant improvement in brachial artery FMD and endothelial function with black cohosh.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Black Cohosh
Search all1048 products whose verified label declares Black Cohosh — not every bottle that mentions it in a title.